CA2572919A1 - Delivery system - Google Patents
Delivery system Download PDFInfo
- Publication number
- CA2572919A1 CA2572919A1 CA002572919A CA2572919A CA2572919A1 CA 2572919 A1 CA2572919 A1 CA 2572919A1 CA 002572919 A CA002572919 A CA 002572919A CA 2572919 A CA2572919 A CA 2572919A CA 2572919 A1 CA2572919 A1 CA 2572919A1
- Authority
- CA
- Canada
- Prior art keywords
- delivery system
- weight percent
- active agent
- propylene glycol
- vaginal cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000839 emulsion Substances 0.000 claims abstract description 39
- 239000013543 active substance Substances 0.000 claims abstract description 38
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 99
- 239000003814 drug Substances 0.000 claims description 15
- 150000002460 imidazoles Chemical class 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 10
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 206010017533 Fungal infection Diseases 0.000 claims description 8
- 208000031888 Mycoses Diseases 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229940121375 antifungal agent Drugs 0.000 claims description 7
- 238000013270 controlled release Methods 0.000 claims description 7
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- 230000000843 anti-fungal effect Effects 0.000 claims description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 5
- 229960002216 methylparaben Drugs 0.000 claims description 5
- 239000002480 mineral oil Substances 0.000 claims description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 5
- 229960003415 propylparaben Drugs 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 229940124274 edetate disodium Drugs 0.000 claims description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000004200 microcrystalline wax Substances 0.000 claims description 4
- 235000019808 microcrystalline wax Nutrition 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 229940049964 oleate Drugs 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004022 clotrimazole Drugs 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 229960000282 metronidazole Drugs 0.000 claims description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229960005074 butoconazole Drugs 0.000 claims 9
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 5
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 229960002509 miconazole Drugs 0.000 claims 2
- 229960003483 oxiconazole Drugs 0.000 claims 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims 2
- 239000003429 antifungal agent Substances 0.000 claims 1
- 230000035587 bioadhesion Effects 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000009102 absorption Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- ZHPWRQIPPNZNML-UHFFFAOYSA-N butoconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 ZHPWRQIPPNZNML-UHFFFAOYSA-N 0.000 description 5
- 229960002120 butoconazole nitrate Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011369 optimal treatment Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- -1 phosphatides Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229960005040 miconazole nitrate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- WVNOAGNOIPTWPT-NDUABGMUSA-N oxiconazole nitrate Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)/CN1C=NC=C1 WVNOAGNOIPTWPT-NDUABGMUSA-N 0.000 description 1
- 229960002894 oxiconazole nitrate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B2017/4216—Operations on uterus, e.g. endometrium
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58627304P | 2004-07-08 | 2004-07-08 | |
| USPCT/US04/22058 | 2004-07-08 | ||
| US60/586,273 | 2004-07-08 | ||
| PCT/US2004/022058 WO2006016869A1 (en) | 2004-07-08 | 2004-07-08 | Delivery system |
| PCT/US2005/024200 WO2006014572A1 (en) | 2004-07-08 | 2005-07-08 | Delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2572919A1 true CA2572919A1 (en) | 2006-02-09 |
Family
ID=35787422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002572919A Abandoned CA2572919A1 (en) | 2004-07-08 | 2005-07-08 | Delivery system |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1765452A4 (cs) |
| CN (2) | CN1771023A (cs) |
| AU (2) | AU2004100776A4 (cs) |
| BR (1) | BRPI0513066A (cs) |
| CA (1) | CA2572919A1 (cs) |
| CZ (1) | CZ15068U1 (cs) |
| ES (1) | ES1060042Y (cs) |
| FR (1) | FR2872702B3 (cs) |
| MX (2) | MXPA04007681A (cs) |
| NL (1) | NL1026978C1 (cs) |
| NZ (1) | NZ552406A (cs) |
| RU (1) | RU2379027C2 (cs) |
| WO (2) | WO2006016869A1 (cs) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2008651A1 (en) * | 2007-06-26 | 2008-12-31 | Drug Delivery Solutions Limited | A bioerodible patch |
| EP2100632A1 (en) | 2008-03-11 | 2009-09-16 | Pantarhei Devices B.V. | Applicator device for body cavity |
| US8308678B2 (en) | 2008-09-23 | 2012-11-13 | Mcneil-Ppc, Inc. | Pre-filled applicator device |
| EP2359750A1 (en) | 2010-02-15 | 2011-08-24 | Delphi Bioscience B.V. | Screening device with valve |
| FR2968004B1 (fr) | 2010-11-29 | 2013-06-28 | Sojasun Technologies | Films naturels biodegradables a base de co-produits issus de processus industriels de traitement de graines. |
| RU2538703C2 (ru) * | 2013-03-12 | 2015-01-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая композиция для лечения вагинального кандидоза и способ ее получения |
| CN108310606A (zh) * | 2015-09-18 | 2018-07-24 | 赵坚 | 一种外用妇科药的给药装置 |
| CN112423826A (zh) * | 2018-06-11 | 2021-02-26 | 宝洁公司 | 用于治疗阴道病症的方法和施用装置 |
| CN112716796B (zh) * | 2018-12-11 | 2022-07-08 | 管云 | 助力配药器 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3045913A1 (de) * | 1980-12-05 | 1982-07-08 | Bayer Ag, 5090 Leverkusen | Antimykotische mittel mit hoher wirkstoff-freisetzung |
| US4636202A (en) * | 1984-07-27 | 1987-01-13 | Syntex (U.S.A.) Inc. | Medicament applicator with plunger assembly and automatically-openable closure therefor |
| US5266329A (en) * | 1985-10-31 | 1993-11-30 | Kv Pharmaceutical Company | Vaginal delivery system |
| US5536743A (en) * | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
| CA1337279C (en) * | 1989-06-06 | 1995-10-10 | Robert J. Borgman | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
| ES2133090B1 (es) * | 1997-02-21 | 2000-04-01 | Uriach & Cia Sa J | Nuevo aplicador para la administracion de medicaciones semisolidas. |
| US6403576B1 (en) * | 1998-08-24 | 2002-06-11 | The United States Of America As Represented By The Secretary Of The Navy | Antifungal and antiparasitic compounds |
| US6740333B2 (en) * | 2000-07-07 | 2004-05-25 | Anestic Aps | Suppository and composition comprising at least one polyethylene glycol |
| RU2207870C2 (ru) * | 2000-11-10 | 2003-07-10 | Панацея Биотек Лимитед | Фармацевтическая композиция, включающая циклоспорин в качестве активного ингредиента |
-
2004
- 2004-07-08 WO PCT/US2004/022058 patent/WO2006016869A1/en active Application Filing
- 2004-07-08 MX MXPA04007681A patent/MXPA04007681A/es unknown
- 2004-08-03 CZ CZ200415701U patent/CZ15068U1/cs not_active IP Right Cessation
- 2004-09-06 NL NL1026978A patent/NL1026978C1/nl not_active IP Right Cessation
- 2004-09-09 ES ES200402091U patent/ES1060042Y/es not_active Expired - Fee Related
- 2004-09-15 AU AU2004100776A patent/AU2004100776A4/en not_active Expired
- 2004-12-22 FR FR0413770A patent/FR2872702B3/fr not_active Expired - Lifetime
-
2005
- 2005-07-08 MX MX2007000109A patent/MX2007000109A/es active IP Right Grant
- 2005-07-08 CN CNA2005800002434A patent/CN1771023A/zh active Pending
- 2005-07-08 NZ NZ552406A patent/NZ552406A/en not_active IP Right Cessation
- 2005-07-08 CA CA002572919A patent/CA2572919A1/en not_active Abandoned
- 2005-07-08 EP EP05769226A patent/EP1765452A4/en not_active Withdrawn
- 2005-07-08 WO PCT/US2005/024200 patent/WO2006014572A1/en active Application Filing
- 2005-07-08 BR BRPI0513066-2A patent/BRPI0513066A/pt not_active IP Right Cessation
- 2005-07-08 CN CN2011101190673A patent/CN102188375A/zh active Pending
- 2005-07-08 RU RU2007104782/14A patent/RU2379027C2/ru not_active IP Right Cessation
- 2005-07-08 AU AU2005269844A patent/AU2005269844A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007104782A (ru) | 2008-08-20 |
| NL1026978C1 (nl) | 2006-01-10 |
| EP1765452A1 (en) | 2007-03-28 |
| FR2872702B3 (fr) | 2006-06-02 |
| CN1771023A (zh) | 2006-05-10 |
| NZ552406A (en) | 2010-07-30 |
| MX2007000109A (es) | 2007-03-26 |
| WO2006016869A1 (en) | 2006-02-16 |
| ES1060042U (es) | 2005-07-16 |
| CZ15068U1 (cs) | 2005-01-31 |
| EP1765452A4 (en) | 2012-11-28 |
| AU2005269844A1 (en) | 2006-02-09 |
| BRPI0513066A (pt) | 2008-04-22 |
| AU2004100776A4 (en) | 2004-11-18 |
| ES1060042Y (es) | 2005-11-01 |
| CN102188375A (zh) | 2011-09-21 |
| FR2872702A3 (fr) | 2006-01-13 |
| MXPA04007681A (es) | 2006-01-12 |
| WO2006014572A1 (en) | 2006-02-09 |
| RU2379027C2 (ru) | 2010-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4551148A (en) | Vaginal delivery systems and their methods of preparation and use | |
| US5266329A (en) | Vaginal delivery system | |
| US10369102B2 (en) | Wax foamable vehicle and pharmaceutical compositions thereof | |
| US9789057B2 (en) | Pharmaceutical delivery system | |
| EP1839643A1 (en) | Cosmetic and pharmaceutical foam carrier | |
| BRPI0612429A2 (pt) | conjunto terapêutico vasoativante e composição terapêutica espumosa | |
| JP2519029B2 (ja) | 腟内送達用製剤 | |
| AU2004100776A4 (en) | Delivery system | |
| US8057433B2 (en) | Delivery system | |
| KR200381664Y1 (ko) | 전달 장치 | |
| JP3106541U (ja) | 送達システム | |
| US20080161376A1 (en) | Method of treating candida isolates | |
| CN2827419Y (zh) | 递送装置 | |
| AU2006332518A1 (en) | Composition and method of use thereof | |
| CA1338977C (en) | Vaginal delivery systems | |
| DE202004012450U1 (de) | Abgabesystem | |
| CA1231052A (en) | Vehicle suitable for use in medicinal preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |